Related Experiment Video
Updated: Mar 23, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
[NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER]
Abstract:
There were observed 30 patients (32 tumors), to whom preoperatively for renal-cell cancer (ROC) a neoadjuvant target therapy (NATTH) was conducted. In 19 (66.7%) of them a pazopanib (800 mg per os once a day through 2 mo) was applied, and in 10 (33.3%)--sunitinib (50 mg per os once a day through 28 days, the gap--14 days, repeated course--28 days). The indications for the NATTH conduction were: in 7 (21.9%) patients--a locally--spread RCC with the objective to localize a tumor and to search a further possibility of radical surgical intervention performance, and in 25 (78.1%)--the tumor reduction and searching possibility of the organpreserving treatment conduction. The NATTH conduction in the patients, suffering RCC, have guaranteed a primary pathological focus reduction in 90% of observations, and a partial regression in accordance to the RECIST criteria--in 28.1%. A tumor reduction by (22.9 ± 17.8)% at average have permitted to perform a renal resection in 75% of observations, concerning localized RCC, when indication of preservation of enough functioning renal parenchyma was secured.
Insights
Neoadjuvant targeted therapy (NATTH) for renal-cell cancer (RCC) significantly reduced tumor size in 90% of patients. This approach facilitated organ-preserving surgery in 75% of localized RCC cases.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Renal-cell cancer (RCC) presents significant treatment challenges.
- Neoadjuvant therapy aims to improve surgical outcomes in RCC.
- Targeted therapies offer novel approaches for managing localized and advanced RCC.
Purpose of the Study:
- To evaluate the efficacy of neoadjuvant targeted therapy (NATTH) in patients with renal-cell cancer (RCC).
- To assess the impact of NATTH on tumor reduction and surgical intervention possibilities.
- To determine the feasibility of organ-preserving treatment following NATTH for localized RCC.
Main Methods:
- A cohort of 30 patients (32 tumors) with RCC received neoadjuvant targeted therapy preoperatively.
- Pazopanib (800 mg/day for 2 months) was administered to 19 patients.
- Sunitinib (50 mg/day for 28 days, with 14-day breaks) was administered to 10 patients.
Main Results:
- NATTH resulted in primary pathological focus reduction in 90% of observed RCC cases.
- Partial regression according to RECIST criteria was observed in 28.1% of patients.
- Average tumor reduction of 22.9% enabled renal resection in 75% of localized RCC cases, preserving renal parenchyma.
Conclusions:
- Neoadjuvant targeted therapy is effective in reducing tumor size in renal-cell cancer.
- NATTH enhances the possibility of performing organ-preserving surgery for localized RCC.
- Targeted therapies like pazopanib and sunitinib show promise in the neoadjuvant setting for RCC management.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Tumor Immunotherapy
02:56Treatment Resistent Cancers